Clinical Report: Could Wegovy Raise Optic Nerve Risk?

Overview

A global pharmacovigilance analysis indicates that the higher-dose semaglutide formulation, Wegovy, is associated with a significantly increased risk of ischemic optic neuropathy (ION) compared to lower-dose formulations. Men are particularly at higher risk, with over three times the odds of reported ION compared to women.

Background

Ischemic optic neuropathy (ION) is a rare but serious condition that can lead to permanent vision loss. Understanding the potential risks associated with medications like semaglutide, especially in its higher-dose formulation used for obesity, is crucial for patient safety. This analysis highlights the importance of monitoring adverse effects in the context of increasing semaglutide prescriptions.

Data Highlights

Key Findings

• The 2.4-mg weekly formulation of semaglutide (Wegovy) has a 4.7-fold higher odds of ION reports compared to the lower-dose formulation (Ozempic).
• Men have over three times the odds of reported ION compared to women.
• No ION reports were identified with the oral formulation of semaglutide (Rybelsus).
• Tirzepatide showed no detectable ION reporting signal in this analysis.
• The absence of an ION signal with oral semaglutide may be due to its low oral bioavailability.
• Stronger reporting signals may reflect higher reporting intensity relative to exposure rather than higher absolute case counts.

Clinical Implications

Healthcare professionals should be vigilant when prescribing Wegovy, particularly for male patients, due to the increased risk of ischemic optic neuropathy. Continuous monitoring and patient counseling regarding potential visual symptoms are essential to ensure timely intervention if ION occurs.

Conclusion

The findings underscore the need for careful consideration of the risks associated with higher-dose semaglutide formulations. Further research is warranted to clarify the causal relationship between semaglutide and ischemic optic neuropathy.

Related Resources & Content

1. European Medicines Agency (EMA), PRAC, 2025 -- PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus and Wegovy
2. PMC, 2024 -- Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide
3. American College of Cardiology, 2023 -- Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity
4. Optometric Management — CLINICAL: Glaucoma
5. Ophthalmology Management — Meeting the Challenge of Normal-Tension Glaucoma
6. Optometric Management — Optical Coherence Tomography Angiography and Glaucoma
7. Retinal Physician — Vitreoretinal Views on Vuity
8. Optometric Management — CLINICAL: Glaucoma
9. Ophthalmology Management — Meeting the Challenge of Normal-Tension Glaucoma
10. Optometric Management — Optical Coherence Tomography Angiography and Glaucoma
11. PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus and Wegovy | European Medicines Agency (EMA)
12. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide - PMC
13. Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity - American College of Cardiology